Julia P. Gregory net worth and biography

Julia Gregory Biography and Net Worth

Director of Nurix Therapeutics

Julia P. Gregory has served as Chair of our board of directors since May 2024 and as a member of our board of directors since August 2019. Ms. Gregory is currently Chair and Chief Executive Officer of Isometry Advisors, Inc., a biotechnology financial, strategy, and management advisory firm. Ms. Gregory formerly served as Chief Executive Officer at ContraFect Corporation, a biotechnology company focused on therapeutics for drug resistant infectious diseases, from November 2013 through March 2016, and as a member of its board of directors from April 2014 through March 2016. Prior to her appointment as Chief Executive Officer, Ms. Gregory served as ContraFect’s Executive Vice President and Chief Financial Officer from July 2012 to November 2013. From 2009 to August 2011, Ms. Gregory served as President and Chief Executive Officer of Five Prime Therapeutics, Inc., and from 2000 to 2008 she served as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. In addition, Ms. Gregory has twenty years of investment banking experience, including at Dillon, Read & Co. and at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory currently serves on the board of directors of Biohaven Ltd. and Spinal Simplicity, LLC. Ms. Gregory holds a B.A. from George Washington University and an M.B.A. from the Wharton School at the University of Pennsylvania.

What is Julia P. Gregory's net worth?: The estimated net worth of Julia P. Gregory is at least $254.45 thousand as of October 14th, 2026. Ms. Gregory owns 10,750 shares of Nurix Therapeutics stock worth more than $254,453 as of October 15th. This net worth evaluation does not reflect any other assets that Ms. Gregory may own. Learn More about Julia P. Gregory's net worth.
How do I contact Julia P. Gregory?: The corporate mailing address for Ms. Gregory and other Nurix Therapeutics executives is 1600 Sierra Point Pkwy, Brisbane, CA, 94005. Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at [email protected]. Learn More on Julia P. Gregory's contact information.
Has Julia P. Gregory been buying or selling shares of Nurix Therapeutics?: Over the course of the past ninety days, Julia P. Gregory has sold $528,442.20 in Nurix Therapeutics stock. Most recently, Julia P. Gregory sold 22,583 shares of the business's stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a transaction totalling $528,442.20. Following the completion of the sale, the director now directly owns 10,750 shares of the company's stock, valued at $251,550. Learn More on Julia P. Gregory's trading history.
Who are Nurix Therapeutics' active insiders?: Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Julia Gregory (Director), Gwenn Hansen (Insider), Christine Ring (General Counsel), and Hans van Houte (CFO). Learn More on Nurix Therapeutics' active insiders.
Are insiders buying or selling shares of Nurix Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 91,063 shares worth more than $1,794,706.06. The most recent insider tranaction occured on October, 14th when Director Julia P. Gregory sold 22,583 shares worth more than $528,442.20. Insiders at Nurix Therapeutics own 6.7% of the company. Learn More about insider trades at Nurix Therapeutics.
Information on this page was last updated on 10/14/2026.

Julia P. Gregory Insider Trading History at Nurix Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/14/2026	Sell	22,583	$23.40	$528,442.20	10,750

Julia P. Gregory Buying and Selling Activity at Nurix Therapeutics

Nurix Therapeutics Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Today's Range

Now: $23.67

$21.40

$24.01

50 Day Range

MA: $25.14

$22.13

$27.79

2 Week Range

Now: $23.67

$9.18

$28.23

Volume

3,820,720 shs

Average Volume

1,859,109 shs

Market Capitalization

$2.46 billion

P/E Ratio

10.25

Dividend Yield

N/A

Beta

1.82